750634-09-4

Basic information

• Product Name: 2-Azabicyclo[2.2.2]octane-2-carboxylic acid, 5-hydroxy-, 1,1-dimethylethyl ester
• Synonyms: 2-Azabicyclo[2.2.2]octane-2-carboxylic acid, 5-hydroxy-, 1,1-dimethylethyl ester;tert-butyl 5-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate
• CAS NO: 750634-09-4
• Molecular Formula: C₁₂H₂₁NO₃
• Molecular Weight: 227.30004
• EINECS: -0
• Mol File: 750634-09-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Azabicyclo[2.2.2]octane-2-carboxylic acid, 5-hydroxy-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Azabicyclo[2.2.2]octane-2-carboxylic acid, 5-hydroxy-, 1,1-dimethylethyl ester(750634-09-4)
• EPA Substance Registry System: 2-Azabicyclo[2.2.2]octane-2-carboxylic acid, 5-hydroxy-, 1,1-dimethylethyl ester(750634-09-4)

Safety Data

• Hazardous Substances Data: 750634-09-4(Hazardous Substances Data)

Upstream product

• 617714-22-4 tert-butyl 5-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate 
• 750634-08-3 2-azabicyclo[2.2.2]octan-5-ol hydrochloride salt 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2597-56-0 4-nitro-o-anisic acid 
• 794468-38-5 2-aza-bicyclo[2.2.2]octan-5-ol 
• 4136-97-4 methyl 4-aminosalicylate 
• 750634-07-2 exo-5-hydroxy-2-azabicyclo-[2.2.2]octan-3-one 
• 13684-28-1 2-hydroxy-4-nitro-benzoic acid methyl ester 
• 619-19-2 2-hydroxy-4-nitrobenzoic acid 

Downstream Products

• 617714-23-5 5-(3,4-Dichloro-benzyl)-2-aza-bicyclo[2.2.2]octane 
• 617714-55-3 5-(3,4-dichlorobenzylidene)-2-aza-bicyclo[2.2.2]octane-2-carboxylic acid tert-butyl ester 
• 750634-10-7 5-(3,4-dichloro-benzyl)-2-aza-bicyclo[2.2.2]octane-2-carboxylic acid tert-butyl ester 
• 617714-22-4 tert-butyl 5-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate 

Relevant articles and documents

OXADIAZOLES AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR

This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where X1; X2; X3; X4; R1 R2 and R4 are as defined herein.

Design and synthesis of novel CCR3 antagonists

As part of our investigation into the development of potent CCR3 antagonists, a series of piperidine analogues was designed and prepared. Exploration of the piperidine core examined both the basicity and the location of a nitrogen, as well as conformational variants. The bicyclo-piperidine 24c was found to be the most potent inhibitor of CCR3 with an IC50 of 0.0082 μM in the binding assay and 0.0024 μM in the chemotaxis assay.